Randomized, Double Blind, Multicenter, Multinational, Placebo Controlled, Single Parallel Escalating Dose, Safety & Efficacy Study of ACT017 Used as add-on of SoC Therapy in the 4,5 Hrs Post Onset of Acute Ischemic Stroke Symptoms
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 17 Jan 2019
At a glance
- Drugs ACT 017 (Primary)
- Indications Stroke
- Focus Adverse reactions
- Acronyms ACTIMIS
- Sponsors Acticor Biotech
- 17 Jan 2019 New source identified and integrated (ClinicalTrials.gov Identifier:NCT03803007)
- 11 Jan 2019 Status changed from planning to not yet recruiting.
- 02 May 2018 Location assumed Europe based on European Medicines Agency has cleared the route for a Phase II trial of ACT017 in stroke.